{"id":56801,"date":"2026-02-10T23:32:34","date_gmt":"2026-02-10T15:32:34","guid":{"rendered":"https:\/\/flcube.com\/?p=56801"},"modified":"2026-02-10T23:32:35","modified_gmt":"2026-02-10T15:32:35","slug":"formosa-pharmaceuticals-licenses-app13007-eye-drops-to-samil-pharma-for-south-korea-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56801","title":{"rendered":"Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market"},"content":{"rendered":"\n

Formosa Pharmaceuticals, Inc.<\/strong> (TPE: 6838<\/a><\/strong>) has entered an exclusive licensing agreement<\/strong> with Samil Pharmaceuticals Co., Ltd.<\/strong> (000520.KS<\/strong>), granting the South Korea-based company commercialization rights<\/strong> to APP13007<\/strong> (clobetasol propionate ophthalmic suspension, 0.05%) for the South Korean market<\/strong>. The patented post\u2011ocular surgery anti\u2011inflammatory<\/strong> therapy expands Formosa’s Asia\u2011Pacific footprint<\/strong> through a local partner with established ophthalmology infrastructure<\/strong>.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Licensor<\/strong><\/td>Formosa Pharmaceuticals, Inc. (TPE: 6838, Taiwan)<\/td><\/tr>
Licensee<\/strong><\/td>Samil Pharmaceuticals Co., Ltd. (000520.KS, South Korea)<\/td><\/tr>
Asset<\/strong><\/td>APP13007 \u2013 Clobetasol propionate ophthalmic suspension, 0.05%<\/td><\/tr>
Territory<\/strong><\/td>South Korea (exclusive)<\/td><\/tr>
Indication<\/strong><\/td>Inflammation and pain following ocular surgery<\/td><\/tr>
Deal Structure<\/strong><\/td>Upfront payment + sales milestones + royalties<\/td><\/tr>
IP Status<\/strong><\/td>Patented innovative medicine<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Profile & Clinical Differentiation<\/h2>\n\n\n\n
Feature<\/th>APP13007 Specification<\/th>Competitive Advantage<\/th><\/tr><\/thead>
Active Ingredient<\/strong><\/td>Clobetasol propionate<\/strong> \u2013 Potent corticosteroid<\/td>High anti\u2011inflammatory efficacy vs. standard post\u2011op drops<\/td><\/tr>
Formulation<\/strong><\/td>Ophthalmic suspension, 0.05%<\/strong><\/td>Optimized ocular penetration and retention<\/td><\/tr>
Indication<\/strong><\/td>Post\u2011ocular surgery inflammation and pain<\/td>Addresses high\u2011volume cataract and refractive surgery markets<\/td><\/tr>
Innovation Status<\/strong><\/td>Patented formulation<\/strong><\/td>Differentiation from generic prednisolone or dexamethasone drops<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Target Market & Strategic Rationale<\/h2>\n\n\n\n
Factor<\/th>Market Context<\/th><\/tr><\/thead>
South Korea Ophthalmology Market<\/strong><\/td>>200,000 cataract surgeries annually<\/strong>; growing refractive surgery (LASIK\/SMILE) volume; established reimbursement for post\u2011op anti\u2011inflammatories<\/td><\/tr>
Samil Positioning<\/strong><\/td>Leading Korean ophthalmology pharma company<\/strong> with existing hospital and clinic relationships; dedicated eye care sales force<\/td><\/tr>
Formosa Regional Strategy<\/strong><\/td>Taiwan\u2011to\u2011Asia expansion<\/strong> leveraging local partners for regulatory, reimbursement, and commercial execution vs. de novo infrastructure<\/td><\/tr>
Corticosteroid Competition<\/strong><\/td>Prednisolone acetate (generic) and Lotemax (bromfenac) dominate; APP13007’s potency and patent protection<\/strong> enables premium positioning<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Development & Commercial Outlook<\/h2>\n\n\n\n
Phase<\/th>Activity<\/th>Timeline<\/th><\/tr><\/thead>
Current<\/strong><\/td>Licensing agreement execution; technology transfer initiation<\/td>Q1 2026<\/td><\/tr>
Regulatory<\/strong><\/td>South Korea MFDS (Ministry of Food and Drug Safety) submission<\/td>2026<\/td><\/tr>
Approval<\/strong><\/td>MFDS marketing authorization<\/td>2026\u20112027<\/td><\/tr>
Launch<\/strong><\/td>Samil commercial rollout to ophthalmology clinics and hospitals<\/td>2027<\/td><\/tr>
Performance<\/strong><\/td>Sales milestones and royalty payments to Formosa<\/td>Ongoing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding APP13007 regulatory approval timelines in South Korea, Samil Pharmaceuticals’ commercial execution, and Formosa Pharmaceuticals’ Asia\u2011Pacific expansion strategy. Actual results may differ due to MFDS review delays, competitive pricing pressure from generic corticosteroids, and ophthalmology market access dynamics in South Korea.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Formosa Pharmaceuticals, Inc. (TPE: 6838) has entered an exclusive licensing agreement with Samil Pharmaceuticals Co.,…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1419,122,4602,1418],"class_list":["post-56801","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-formosa-pharmaceuticals","tag-mobile-health-app","tag-samil-pharmaceuticals","tag-tpe-6838"],"yoast_head":"\nFormosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Formosa Pharmaceuticals, Inc. (TPE: 6838) has entered an exclusive licensing agreement with Samil Pharmaceuticals Co., Ltd. (000520.KS), granting the South Korea-based company commercialization rights to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%) for the South Korean market. The patented post\u2011ocular surgery anti\u2011inflammatory therapy expands Formosa's Asia\u2011Pacific footprint through a local partner with established ophthalmology infrastructure.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56801\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market\" \/>\n<meta property=\"og:description\" content=\"Formosa Pharmaceuticals, Inc. (TPE: 6838) has entered an exclusive licensing agreement with Samil Pharmaceuticals Co., Ltd. (000520.KS), granting the South Korea-based company commercialization rights to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%) for the South Korean market. The patented post\u2011ocular surgery anti\u2011inflammatory therapy expands Formosa's Asia\u2011Pacific footprint through a local partner with established ophthalmology infrastructure.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56801\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-10T15:32:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-10T15:32:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56801#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56801\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market\",\"datePublished\":\"2026-02-10T15:32:34+00:00\",\"dateModified\":\"2026-02-10T15:32:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56801\"},\"wordCount\":363,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Formosa Pharmaceuticals\",\"Mobile health \\\/ APP\",\"Samil Pharmaceuticals\",\"TPE: 6838\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56801#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56801\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56801\",\"name\":\"Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-10T15:32:34+00:00\",\"dateModified\":\"2026-02-10T15:32:35+00:00\",\"description\":\"Formosa Pharmaceuticals, Inc. (TPE: 6838) has entered an exclusive licensing agreement with Samil Pharmaceuticals Co., Ltd. (000520.KS), granting the South Korea-based company commercialization rights to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%) for the South Korean market. The patented post\u2011ocular surgery anti\u2011inflammatory therapy expands Formosa's Asia\u2011Pacific footprint through a local partner with established ophthalmology infrastructure.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56801#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56801\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56801#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market - Insight, China's Pharmaceutical Industry","description":"Formosa Pharmaceuticals, Inc. (TPE: 6838) has entered an exclusive licensing agreement with Samil Pharmaceuticals Co., Ltd. (000520.KS), granting the South Korea-based company commercialization rights to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%) for the South Korean market. The patented post\u2011ocular surgery anti\u2011inflammatory therapy expands Formosa's Asia\u2011Pacific footprint through a local partner with established ophthalmology infrastructure.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56801","og_locale":"en_US","og_type":"article","og_title":"Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market","og_description":"Formosa Pharmaceuticals, Inc. (TPE: 6838) has entered an exclusive licensing agreement with Samil Pharmaceuticals Co., Ltd. (000520.KS), granting the South Korea-based company commercialization rights to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%) for the South Korean market. The patented post\u2011ocular surgery anti\u2011inflammatory therapy expands Formosa's Asia\u2011Pacific footprint through a local partner with established ophthalmology infrastructure.","og_url":"https:\/\/flcube.com\/?p=56801","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-10T15:32:34+00:00","article_modified_time":"2026-02-10T15:32:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56801#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56801"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market","datePublished":"2026-02-10T15:32:34+00:00","dateModified":"2026-02-10T15:32:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56801"},"wordCount":363,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Formosa Pharmaceuticals","Mobile health \/ APP","Samil Pharmaceuticals","TPE: 6838"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56801#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56801","url":"https:\/\/flcube.com\/?p=56801","name":"Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-10T15:32:34+00:00","dateModified":"2026-02-10T15:32:35+00:00","description":"Formosa Pharmaceuticals, Inc. (TPE: 6838) has entered an exclusive licensing agreement with Samil Pharmaceuticals Co., Ltd. (000520.KS), granting the South Korea-based company commercialization rights to APP13007 (clobetasol propionate ophthalmic suspension, 0.05%) for the South Korean market. The patented post\u2011ocular surgery anti\u2011inflammatory therapy expands Formosa's Asia\u2011Pacific footprint through a local partner with established ophthalmology infrastructure.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56801#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56801"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56801#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56801","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56801"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56801\/revisions"}],"predecessor-version":[{"id":56802,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56801\/revisions\/56802"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56801"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56801"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56801"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}